CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Public ClinicalTrials.gov record NCT02187302. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to treatment with a standard of care therapy. The study will compare which treatment resulted in longer time before progression of the RCC. Patients will be treated and followed for progression of their disease on average for up to 6 months.
Study identification
- NCT ID
- NCT02187302
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 115 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2014 (Type not available)
- Primary completion
- Jul 2016 (Actual)
- Completion
- Jan 2017 (Actual)
- Last update posted
- May 28, 2020
2014 – 2017
United States locations
- U.S. sites
- 38
- U.S. states
- 23
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego | La Jolla | California | 92093 | — |
| David Geffen School of Medicine UCLA | Los Angeles | California | 90024 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Kaiser Permanente | Honolulu | Hawaii | 96819 | — |
| Decatur Memorial Hospital | Decatur | Illinois | 62526 | — |
| Indiana University School of Medicine | Indianapolis | Indiana | 46202 | — |
| Franciscan St. Francis Health | Indianapolis | Indiana | 46237 | — |
| June E. Nylen Cancer Center | Sioux City | Iowa | 51101 | — |
| The University of Kansas Cancer Center | Fairway | Kansas | 66205 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Our Lady of the Lake Physician Group | Baton Rouge | Louisiana | 70808 | — |
| University of Maryland, Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Ann Arbor Hematoloty-Oncology | Ann Arbor | Michigan | 48106 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| North Mississippi Hematology and Oncology Associates | Tupelo | Mississippi | 38801 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68130 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| MD Anderson Cooper Cancer Institute | Voorhees Township | New Jersey | 08043 | — |
| New York Oncology Hematology | Albany | New York | 12208 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| UNC Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
| Cancer Centers of the Carolinas | Greenville | South Carolina | 29615 | — |
| Texas Oncology, Amarillo | Amarillo | Texas | 79106 | — |
| Texas Oncology P.A. | Austin | Texas | 78745 | — |
| Texas Oncology, Dallas | Dallas | Texas | 75246 | — |
| Texas Oncology, El Paso | El Paso | Texas | 79902 | — |
| Texas Oncology, Flower Mound | Flower Mound | Texas | 75028 | — |
| Texas Oncology, Fort Worth | Fort Worth | Texas | 76104 | — |
| Texas Oncology, P.A. | Houston | Texas | 77024 | — |
| Cancer Center Network of South Texas | San Antonio | Texas | 78217 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| CAMC Health Education and Research Institute | Charleston | West Virginia | 25304 | — |
| St. Vincent Regional Cancer Center CCOP | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02187302, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2020 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02187302 live on ClinicalTrials.gov.